Clinical trials: Esophagogastric Adenocarcinoma
Esophagogastric Junction Adenocarcinoma
Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction Adenocarcinoma
The purpose of this study is to access the safety and efficacy of neoadjuvant Immunotherapy (Sintilimab, PD-1 inhibitor) combined with chemotherapy (Tegafur+Oxaliplatin) for locally advanced esophagogastric junction…
- Trial name
- NCT05170503
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Sun Yat-sen University
Fluorescence Laparoscopy, Adenocarcinoma of the Esophagogastric Junction
The Application of Fluorescence Laparoscopy in the Treatment of Adenocarcinoma of the Esophagogastric Junction
The fluorescent laparoscopic technique would be applied to the radical resection of gastric cancer at the junction of esophagus and stomach, and compared with the traditional laparoscopic radical resection of gastric cancer to…
- Trial name
- NCT03647540
- Testing
- fluorescent laparoscopic radical gastrectomy, traditional laparoscopic radical gastrectomy
- Where
- China
- Volunteers
- 164 people
- Sponsor
- Dong Yang
Esophagogastric Adenocarcinoma
Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma
This is a single-arm phase I/Ib study of crenolanib combined with ramucirumab/paclitaxel as second line therapy for patients with advanced/metastatic adenocarcinoma of the esophagus, GEJ or stomach.
- Trial name
- NCT03193918
- Testing
- Crenolanib, Ramucirumab, Paclitaxel
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Arog Pharmaceuticals, Inc.
Gastric Cancer, Cancer of the Stomach
An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers
The purpose of this study is to determine the efficacy and safety of investigational drug relatlimab plus nivolumab in combination with chemotherapy in participants with unresectable, untreated, locally advanced or metastatic…
- Conditions
- Gastric Cancer, Cancer of the Stomach, Esophagogastric Junction
- Trial name
- NCT03662659
- Testing
- BMS-986213, Nivolumab, XELOX
- Where
- 79 sites in United States, Argentina and 15 more
- Volunteers
- 274 people
- Sponsor
- Bristol-Myers Squibb
Carcinoma, Gastrointestinal Diseases
XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma
This is an open label, randomized, phase Ⅱ, multi-cohort study to treat subjects with ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma.
- Conditions
- Carcinoma, Gastrointestinal Diseases, Stomach Cancer, Gastroesophageal-junction Cancer
- Trial name
- EXPLORING (NCT05494060)
- Testing
- Anlotinib hydrochloride capsule, Penpulimab Injection, XELOX
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Adenocarcinoma of Esophagogastric Junction, Neoadjuvant Chemotherapy
Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ Adenocarcinoma
The purpose of this study is to observe and evaluate the efficacy and safety of pembrolizumab plus cisplatin and 5-fluorouracil (5-FU) followed Surgery for locally advanced adenocarcinoma of esophagogastric junction
- Conditions
- Adenocarcinoma of Esophagogastric Junction, Neoadjuvant Chemotherapy, Pembrolizumab
- Trial name
- KEYSTONE-003 (NCT04813523)
- Testing
- Pembrolizumab Injection [Keytruda]
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction
mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA
The aim of this study was to compare the efficacy and safety of mFOLFOX, mFOLFIRI and FOLFPTX as first-line treatment in AGC or EGJA.
- Trial name
- NCT03045770
- Testing
- Fluorouracil, Oxaliplatin, Irinotecan
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Fujian Cancer Hospital
Solid Tumor, Gastric Cancer
Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors
This is an open, two-stage, phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of AB011 injection in patients with CLDN18.2-positive advanced solid tumors.
- Conditions
- Solid Tumor, Gastric Cancer, Pancreatic Adenocarcinoma
- Trial name
- NCT04400383
- Testing
- AB011 Injection
- Where
- 12 sites in China
- Volunteers
- 62 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Esophageal Cancer
A Biomarker-driven Therapeutic Strategy for Esophageal Cancer Chemoradiotherapy in Patients With Resectable Adenocarcinoma of the ESophagus and Esophagogastric Junction
Preoperative chemoradiotherapy followed by surgery has been accepted as the standard of care for resectable adenocarcinoma of the esophagus and esophagogastric junction (EGJ).
- Trial name
- BoRgES (NCT04269083)
- Testing
- BIRC3
- Volunteers
- 128 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Gastric Cancers, Esophagogastric Junction Cancers
QL1706 Combined With SOX Used in Theperioperative Treatment
This is a single-center, single-arm clinical study to evaluate the efficacy and safety of QL1706 combined with SOX for the treatment of resectable locally advanced gastric or gastroesophageal junction adenocarcinoma.
- Trial name
- NCT06766305
- Testing
- QL1706 combined with SOX
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Xiangdong Cheng
PD-1, Neoadjuvant Chemoradiotherapy
Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction
The purpose of this study is to access the safety and efficacy of neoadjuvant Immunotherapy (Sintilimab, PD-1 inhibitor) combined with chemotherapy (S-1+Oxaliplatin) and radiotherapy for locally advanced esophagogastric junction…
- Conditions
- PD-1, Neoadjuvant Chemoradiotherapy, Gastroesophageal Junction Cancer
- Trial name
- NCT06250894
- Testing
- PD-1inhibitor
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Anemia, Esophageal Cancer
Iron Replacement in Oesophagogastric Neoplasia
40 eligible patients with confirmed esophageal or gastric adenocarcinoma and anemia will be randomized to a control or intervention group for management of this anemia.
- Conditions
- Anemia, Esophageal Cancer, Gastric Cancer
- Trial name
- IRON (NCT01927328)
- Testing
- Iron isomaltoside 1000
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Nottingham University Hospitals NHS Trust
Esophagogastric Adenocarcinoma
Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma
This is a phase II study of OBP-301 with pembrolizumab in advanced gastric and gastroesophageal junction adenocarcinoma that has progressed on at least 2 lines of prior therapy for advanced disease.
- Trial name
- NCT03921021
- Testing
- Telomelysin
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Weill Medical College of Cornell University
Adenocarcinoma,Stomach, Adenocarcinoma, Esophagogastric Junction
Feasibility Study of Adjuvant Treatment With S-1 in Patients After R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction
Multicenter trial in Germany: Feasibility Study of Adjuvant Treatment with S-1 in Patients after R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction with the aim to show the feasibility and tolerability of…
- Trial name
- S-1 adjuvant (NCT02564367)
- Testing
- S-1
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- AIO-Studien-gGmbH
Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma
Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ
This study is a prospective, single-arm, phase II clinical study. Screening patients with stage III GC/GEJ adenocarcinoma after D2 or broader radical resection.
- Trial name
- NCT06761846
- Testing
- Sintilimab plus Chemotherapy
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Stomach Neoplasms, Esophagogastric Junction Disorder
Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer
NeoRacing is a randomized phase II trial carried out at Fudan University Shanghai Cancer Center (FUSCC) in China. The study can be divided into the screening stage, treatment stage and follow-up stage.
- Conditions
- Stomach Neoplasms, Esophagogastric Junction Disorder, Neoadjuvant Therapy, Chemoradiotherapy
- Trial name
- NeoRacing (NCT05161572)
- Testing
- Oxaliplatin, Tegafur-Gimeracil-Oteracil, Sintilimab
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Fudan University
Proximal Gastric Adenocarcinoma, Gastric Cancer
Proximal Gastrectomy Anterior Anastomosis With Pyloroplasty Versus Esophagogastric Anastomosis for Gastric Cancer
This research is designed to compare proximal gastrectomy anterior anastomosis with pyloroplasty with esophagogastric anastomosis for gastric cancer.
- Conditions
- Proximal Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Reflux Disease
- Trial name
- NCT05514769
- Testing
- Proximal Gastrectomy Anterior Anastomosis With Pyloroplasty
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Nanchong Central Hospital
Esophageal Neoplasms, Stomach Neoplasms
Study Assessing the Effects of Chemotherapy in Advanced Esophagogastric Adenocarcinoma
The main purpose of this study is to determine the effects of treatment with carboplatin, docetaxel and capecitabine in patients with incurable cancer of the esophagus or stomach.
- Trial name
- SEED (NCT02177552)
- Testing
- Carboplatin, Docetaxel, Capecitabine
- Where
- Denmark
- Volunteers
- 98 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Basal Cell Carcinoma, Medulloblastoma
A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics, and determine the maximum tolerated dose of ZSP1602 in participants with basal cell carcinoma, adenocarcinoma of esophagogastric junction…
- Conditions
- Basal Cell Carcinoma, Medulloblastoma, Adenocarcinoma of Esophagogastric Junction, Small Cell Lung Cancer
- Trial name
- NCT03734913
- Testing
- ZSP1602
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Gastric Adenocarcinoma, Esophagogastric Juction Cancer
Tafolecimab Combined With Sintilimab and SOX in the Treatment of pMMR/MSS Gastric Cancer
Background: Gastric cancer remains a significant health burden globally, particularly in China, where the majority of patients present with advanced disease at diagnosis.
- Conditions
- Gastric Adenocarcinoma, Esophagogastric Juction Cancer, Proficient Mismatch Repair
- Trial name
- NCT07621562
- Testing
- Tafolecimab plus Sintilimab combined with SOX
- Where
- China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital of Zhejiang University